Table 1 BH3-mimetics in clinical development
From: The BCL2 family: from apoptosis mechanisms to new advances in targeted therapy
Name | Target | Status | Original Ref |
|---|---|---|---|
Venetoclax / ABT-199 | BCL2 | FDA approved | |
Sonrotoclax / BGB11417 | BCL2 | Phase III | |
Lisaftoclax / APG-2575 | BCL2 | Phase III | |
ABBV-453 | BCL2 | Phase I | unpublished |
ABBV-623 | BCL2 | Terminated | unpublished |
S55746 / BCL201 | BCL2 | Phase I completed | |
S65487 / VOB560 | BCL2 | Phase I (halted) | |
FCN-338 / LOXO-338 | BCL2 | Phase I | |
BGB21447 | BCL2 | Phase I | unpublished |
ZN-d5 | BCL2 | Phase I/II | |
Lacutoclax / LP-108 | BCL2 | Phase I/II | |
TQB3909 | BCL2 | Phase I/II | unpublished |
Navitoclax / ABT-263 | BCL2/BCL-XL | Phase III | |
AZD4320 and AZD0466 | BCL2/BCL-XL | Terminated | |
Pelcitoclax / APG-1252 | BCL2/BCL-XL | Phase I | |
Mirzotamab Clezutoclax / ABBV-155 (ADC) | BCL-XL | Phase I (halted) | |
ABBV-637 (ADC) | BCL-XL | Phase I (halted) | |
MIK665 / S64315 | MCL1 | Phase I (halted) | |
AZD5991 | MCL1 | Phase I | |
Tapotoclax / AMG176 | MCL1 | Phase I (halted) | |
Murizatoclax / AMG397 | MCL1 | Terminated | |
Zamzetoclax/ GS9716 | MCL1 | Phase I | |
ABBV-467 | MCL1 | Terminated | |
PRT1419 | MCL1 | Terminated |
